. 2022 Jan 12;27:2515690X211068826. doi: 10.1177/2515690X211068826

Table 5.

Bladder.

Year, Ref.	Findings
2017²⁵³	Silibinin reversed chemotherapeutic resistance in bladder cancer cells in a NF-kB signal-dependent and independent manner.
2017³¹⁵	Silibinin is an antiproliferative compound whose mechanism of action depended on p53 status (WT or mutated).
2002³¹⁶ X	In an induced bladder carcinogenesis mouse model, silymarin reduced the incidence of bladder lesions and cell proliferation. Silymarin acted as a preventive compound.
2017³¹⁷	The anticancer mechanism of silibinin in bladder cancer was through downregulation of the actin cytoskeleton, the PI3K/Akt pathway and KRAS.
2011³¹⁸ X	Oral silibinin prevented carcinogenesis, decreased proliferation, and increased apoptosis in vivo in a mouse model. Intravesical silibinin had a similar effect.
2013³¹⁹ X	Silibinin decreased bladder cancer metastasis and prolonged animal survival through downregulation of the GSK3β/β catenin pathway and Zeb1 expression. Silibinin also suppressed EMT and stemness.